ZYNLONTA: ADC Therapeutics' Growth Driver

ADC Therapeutics reports steady progress in Q4 2025, with ZYNLONTA sales up 37% YoY to $22.3M, totaling $73.6M for the year. Operating costs cut by 50% through strategic reprioritization. LOTIS-five and LOTIS-seven trials show promising results. ZYNLONTA holds a strong position in third-line DLBCL therapy, with potential to gain share in second-line settings. Financials stable, with cash pile of $261M funding operations until 2028. Key catalysts include LOTIS-five top-line data in Q2 2026, targeting approvals and compendia listings. Peak U.S. revenue potential of $600M-$1B if trials succeed, positioning ZYNLONTA as a backbone therapy for growth starting 2027. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fb46c147301faa3a